Benzodiazepines: Risks and benefits. A reconsideration

Journal of Psychopharmacology

Volumn 27, Issue 11, 2013, Pages 967-971

  Baldwin, David S ^a   Aitchison, Katherine ^b   Bateson, Alan ^c   Curran, H Valerie ^d   Davies, Simon ^e   Leonard, Brian ^f   Nutt, David J ^g   Stephens, David N ^h   Wilson, Sue ^g  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

^f NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

benefits; Benzodiazepines; pharmacology; risks; withdrawal

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; COCAINE; DIAMORPHINE; DIAZEPAM; DRUG METABOLITE; FLUNITRAZEPAM; HYPNOTIC AGENT; LORAZEPAM; NEUROSTEROID; TEMAZEPAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANTEROGRADE AMNESIA; ANXIETY DISORDER; BEHAVIOR DISORDER; BENZODIAZEPINE DEPENDENCE; BIPOLAR DISORDER; DEPRESSION; DROWSINESS; DRUG HALF LIFE; DRUG USE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MANIA; MEDICAL SOCIETY; MENTAL FUNCTION; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE;

BENEFITS; BENZODIAZEPINES; PHARMACOLOGY; RISKS; WITHDRAWAL;

BENZODIAZEPINES; HUMANS; HYPNOTICS AND SEDATIVES; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84885706708     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113503509     Document Type: Review

References (7)

1. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
2. Chick J, Nutt DJ. Substitution therapy for alcoholism: Time for a reappraisal?. J Psychopharmacol. 2011 ; 26: 205-212
3. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders?. A critical reappraisal. Eur Psychiatry. 2013 ; 28: 7-20
4. Lingford-Hughes A, Welch S, Peters L, et al. BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. J Psychopharmacol. 2012 ; 26: 899-952
5. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol. 2008 ; 22: 3-6
6. Stephens DN, King SL Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders. Blume AW Kavanagh DJ Kampman KM, ed. San Diego, USA: Academic Press ; 2013: 605-614.
7. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 ; 24: 1577-1600